Business Context and Reporting Period
Zymeworks Inc. (ZYME) filed a Current Report on Form 8-K dated June 26, 2025. The filing reports the entry into a material definitive agreement and the unregistered sale of equity securities involving the company's Pre-Funded Warrants issued to EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. (collectively, the "Purchasers").
Key Financial Metrics and Transaction Details
- Transaction Type: Full net exercise of 5,086,521 Pre-Funded Warrants.
- Shares Issued: 5,086,480 shares of Common Stock issued on June 27, 2025.
- Exercise Price: $0.0001 per share.
- Original Investment: The Purchasers originally acquired the warrants on December 28, 2023, for an aggregate purchase price of approximately $50 million ($9.8299 per warrant).
- Post-Transaction Outstanding Shares: 74,844,505 shares as of June 27, 2025.
- Liquidity and Debt: The filing does not provide updated cash flow, debt, or liquidity metrics beyond the specific transaction details.
Material Changes Versus Prior Period
The primary material change is the removal of a beneficial ownership limitation on the Pre-Funded Warrants. Previously, Section 12 of the warrants prohibited exercise if the Purchaser's aggregate beneficial ownership would exceed 19.99% of the Company's outstanding Common Stock. The Amendment dated June 26, 2025, removed this restriction, enabling the full net exercise of the warrants.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the issuance was exempt from registration under Section 3(a)(9) of the Securities Act of 1933. The transaction involved no commissions or remuneration paid for solicitation.
Key Facts for Investor Verification
- Verify the updated total share count of 74,844,505 and the resulting ownership percentage of the Purchasers (EcoR1) post-exercise.
- Confirm the impact of the 5,086,480 newly issued shares on existing shareholder dilution.
- Review the attached Amendment (Exhibit 10.1) for any other modified terms regarding the Pre-Funded Warrants.
- Note that the Purchasers, who hold board seats, now hold a significant portion of the company's equity following the removal of the 19.99% exercise cap.